Defining CRISPR-Cas9 genome-wide nuclease activities with CIRCLE-seq

被引:62
|
作者
Lazzarotto, Cicera R. [1 ]
Nguyen, Nhu T. [2 ,3 ,6 ,7 ]
Tang, Xing [1 ]
Malagon-Lopez, Jose [2 ,3 ,4 ,5 ]
Guo, Jimmy A. [2 ,3 ]
Aryee, Martin J. [2 ,3 ,4 ,5 ]
Joung, J. Keith [2 ,3 ,4 ]
Tsai, Shengdar Q. [1 ]
机构
[1] St Jude Childrens Res Hosp, Dept Hematol, 332 N Lauderdale St, Memphis, TN 38105 USA
[2] Massachusetts Gen Hosp, Mol Pathol Unit, Ctr Canc Res, Charlestown, MA USA
[3] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Charlestown, MA USA
[4] Harvard Med Sch, Dept Pathol, Boston, MA USA
[5] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA
[6] Massachusetts Gen Hosp, Dept Dermatol, Cutaneous Biol Res Ctr, Boston, MA 02114 USA
[7] Harvard Med Sch, Boston, MA USA
基金
美国国家卫生研究院;
关键词
DOUBLE-STRANDED BREAKS; OFF-TARGET CLEAVAGE; DNA; SPECIFICITIES;
D O I
10.1038/s41596-018-0055-0
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Circularization for in vitro reporting of cleavage effects by sequencing (CIRCLE-seq) is a sensitive and unbiased method for defining the genome-wide activity (on-target and off-target) of CRISPR-Cas9 nucleases by selective sequencing of nuclease-cleaved genomic DNA (gDNA). Here, we describe a detailed experimental and analytical protocol for CIRCLE-seq. The principle of our method is to generate a library of circularized gDNA with minimized numbers of free ends. Highly purified gDNA circles are treated with CRISPR-Cas9 ribonucleoprotein complexes, and nuclease-linearized DNA fragments are then ligated to adapters for high-throughput sequencing. The primary advantages of CIRCLE-seq as compared with other in vitro methods for defining genome-wide genome editing activity are (i) high enrichment for sequencing nuclease-cleaved gDNA/low background, enabling sensitive detection with low sequencing depth requirements; and (ii) the fact that paired-end reads can contain complete information on individual nuclease cleavage sites, enabling use of CIRCLE-seq in species without high-quality reference genomes. The entire protocol can be completed in 2 weeks, including time for gRNA cloning, sequence verification, in vitro transcription, library preparation, and sequencing.
引用
收藏
页码:2615 / 2642
页数:28
相关论文
共 50 条
  • [21] Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening
    Michael K. Kiessling
    Sven Schuierer
    Silke Stertz
    Martin Beibel
    Sebastian Bergling
    Judith Knehr
    Walter Carbone
    Cheryl de Vallière
    Joelle Tchinda
    Tewis Bouwmeester
    Klaus Seuwen
    Gerhard Rogler
    Guglielmo Roma
    BMC Genomics, 17
  • [22] Genome-wide CRISPR-Cas9 screens reveal modulators of temozolomide sensitivity in glioblastoma
    MacLeod, Graham
    Rajakulendran, Nishani
    Hart, Traver
    Yu, Helen
    Dirks, Peter B.
    Angers, Stephane
    MOLECULAR CANCER THERAPEUTICS, 2017, 16 (10)
  • [23] Nomination of Genome-Wide CRISPR-Cas9 Cleavage Activity Using rhAmp Technology
    Turk, Rolf
    Kinney, Kyle
    Zhang, He
    Osborne, Thomas
    Wang, David
    Rettig, Garrett
    MOLECULAR THERAPY, 2024, 32 (04) : 790 - 790
  • [24] The application of genome-wide CRISPR-Cas9 screens to dissect the molecular mechanisms of toxins
    Wang, Bei
    Chen, Jun-Zhu
    Luo, Xue-Qun
    Wan, Guo-Hui
    Tang, Yan-Lai
    Wang, Qiao-Ping
    COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL, 2022, 20 : 5076 - 5084
  • [25] A systematic genome-wide mapping of oncogenic mutation selection during CRISPR-Cas9 genome editing
    Sanju Sinha
    Karina Barbosa
    Kuoyuan Cheng
    Mark D. M. Leiserson
    Prashant Jain
    Anagha Deshpande
    David M. Wilson
    Bríd M. Ryan
    Ji Luo
    Ze’ev A. Ronai
    Joo Sang Lee
    Aniruddha J. Deshpande
    Eytan Ruppin
    Nature Communications, 12
  • [26] A systematic genome-wide mapping of oncogenic mutation selection during CRISPR-Cas9 genome editing
    Sinha, Sanju
    Barbosa, Karina
    Cheng, Kuoyuan
    Leiserson, Mark D. M.
    Jain, Prashant
    Deshpande, Anagha
    Wilson, David M., III
    Ryan, Brid M.
    Luo, Ji
    Ronai, Ze'ev A.
    Lee, Joo Sang
    Deshpande, Aniruddha J.
    Ruppin, Eytan
    NATURE COMMUNICATIONS, 2021, 12 (01)
  • [27] Genome-wide CRISPR-Cas9 screens identify mechanisms of BET bromodomain inhibitor sensitivity
    Estoppey, David
    Schutzius, Gabi
    Kolter, Christian
    Salathe, Adrian
    Wunderlin, Tiffany
    Meyer, Amandine
    Nigsch, Florian
    Bouwmeester, Tewis
    Hoepfner, Dominic
    Kirkland, Susan
    ISCIENCE, 2021, 24 (11)
  • [28] Genome-Wide Off-Target Analysis in CRISPR-Cas9 Modified Mice and Their Offspring
    Dong, Yan
    Li, Haimei
    Zhao, Liang
    Koopman, Peter
    Zhang, Feng
    Huang, Johnny X.
    G3-GENES GENOMES GENETICS, 2019, 9 (11): : 3645 - 3651
  • [29] The genomic landscape of sensitivity to arsenic trioxide uncovered by genome-wide CRISPR-Cas9 screening
    Chen, Jun-Zhu
    Wang, Li-Na
    Luo, Xue-Qun
    Tang, Yan-Lai
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [30] Identifying mechanisms of acquired resistance to lorlatinib utilizing a genome-wide CRISPR-Cas9 screen
    Kalna, Joshua Renn
    Matkar, Smita
    O'Drisoll, Emily
    Balyasny, Skye
    Calafatti, Matteo
    Gerelus, Mark
    Groff, Dave
    Acholla, Tina
    Casey, Colleen E.
    Kamitsuka, Paul
    Li, Grant
    Pastor, Steven J.
    Witek, Gabriela
    Krytska, Kateryna
    Lindsay, Jarrett
    Shalem, Ophir
    Mosse, Yael P.
    CANCER RESEARCH, 2024, 84 (06)